News
A phase 1 study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: Dose-expansion results from the NiraPim (EPOC2102) study. Genomic landscape of 5’methylthioadenosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback